HK1204547A1 - Compound comprising a mao targeting/ seeker moiety for treating human gliomas - Google Patents
Compound comprising a mao targeting/ seeker moiety for treating human gliomas Download PDFInfo
- Publication number
- HK1204547A1 HK1204547A1 HK15103179.0A HK15103179A HK1204547A1 HK 1204547 A1 HK1204547 A1 HK 1204547A1 HK 15103179 A HK15103179 A HK 15103179A HK 1204547 A1 HK1204547 A1 HK 1204547A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compound
- targeting
- mao
- human gliomas
- treating human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553854P | 2011-10-31 | 2011-10-31 | |
| US61/553,854 | 2011-10-31 | ||
| PCT/US2012/062850 WO2013151584A1 (en) | 2011-10-31 | 2012-10-31 | Compound comprising a mao targeting/ seeker moiety for treating human gliomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1204547A1 true HK1204547A1 (en) | 2015-11-27 |
Family
ID=47146760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15103179.0A HK1204547A1 (en) | 2011-10-31 | 2012-10-31 | Compound comprising a mao targeting/ seeker moiety for treating human gliomas |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10555936B2 (enExample) |
| EP (2) | EP2804604A1 (enExample) |
| JP (1) | JP6118808B2 (enExample) |
| KR (1) | KR102110794B1 (enExample) |
| CN (1) | CN104136026B (enExample) |
| AU (1) | AU2012376221A1 (enExample) |
| CA (1) | CA2887928A1 (enExample) |
| HK (1) | HK1204547A1 (enExample) |
| WO (1) | WO2013151584A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1204547A1 (en) | 2011-10-31 | 2015-11-27 | The Methodist Hospital | Compound comprising a mao targeting/ seeker moiety for treating human gliomas |
| CN104710433B (zh) * | 2014-01-23 | 2016-08-17 | 南京友怡医药科技有限公司 | 苯丁酸氮芥衍生物、制备方法及应用 |
| US10807944B2 (en) * | 2014-04-04 | 2020-10-20 | University Of Florida Research Foundation, Inc. | HDAC inhibitor compounds and methods of treatment |
| JP2024511277A (ja) | 2021-02-19 | 2024-03-13 | メビオン・メディカル・システムズ・インコーポレーテッド | 粒子線治療システムのためのガントリー |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4913891A (en) * | 1986-04-17 | 1990-04-03 | The United States Of America As Represented By The United States Department Of Energy | Positron emitter labeled enzyme inhibitors |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| CA2164518A1 (en) * | 1993-06-07 | 1994-12-22 | Cristopher D.V. Black | Immunoreactive reagents employing monoamine oxidase |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5612329A (en) | 1995-06-05 | 1997-03-18 | University Of Maryland At Baltimore | Diaziridinylpolyamine anti-cancer agents |
| WO1998022110A1 (en) * | 1996-11-20 | 1998-05-28 | Virginia Tech Intellectual Properties, Inc. | Prodrugs for the selective inhibition of monoamine oxidase-b |
| IL145089A0 (en) | 1999-03-03 | 2002-06-30 | Procter & Gamble | Alkenyl-and alkynyl-containing metalloprotease inhibitors |
| US6750345B2 (en) | 2000-11-07 | 2004-06-15 | Symyx Technologies, Inc. | Substituted pyridyl amine catalysts, complexes and compositions |
| US6946479B2 (en) | 2002-11-09 | 2005-09-20 | The Procter & Gamble Company | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones |
| WO2004110255A2 (en) | 2003-06-09 | 2004-12-23 | Gang Zheng | Antineoplastic agents targeted via glut transporters |
| EP1758887A1 (en) * | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US7091205B2 (en) | 2004-10-08 | 2006-08-15 | Yu Show Fu | Use of tetramethylpyrazine in the treatment of brain tumor |
| GB0513297D0 (en) | 2005-06-29 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
| US20070275944A1 (en) | 2006-04-05 | 2007-11-29 | The Board Of Trustees Operating Michigan State University | Antioxidants and methods of their use |
| AR070317A1 (es) * | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
| WO2009111278A2 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| EP2141163A1 (de) * | 2008-07-02 | 2010-01-06 | Bayer Schering Pharma AG | Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| EP3613729A1 (en) * | 2009-06-10 | 2020-02-26 | Chugai Seiyaku Kabushiki Kaisha | Tetracyclic compounds |
| WO2011035332A1 (en) * | 2009-09-21 | 2011-03-24 | Chemocentryx, Inc. | Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators |
| HK1204547A1 (en) | 2011-10-31 | 2015-11-27 | The Methodist Hospital | Compound comprising a mao targeting/ seeker moiety for treating human gliomas |
-
2012
- 2012-10-31 HK HK15103179.0A patent/HK1204547A1/xx unknown
- 2012-10-31 EP EP12783818.3A patent/EP2804604A1/en not_active Withdrawn
- 2012-10-31 EP EP20189611.5A patent/EP3815685A3/en not_active Withdrawn
- 2012-10-31 KR KR1020147014835A patent/KR102110794B1/ko active Active
- 2012-10-31 CN CN201280064763.1A patent/CN104136026B/zh not_active Expired - Fee Related
- 2012-10-31 AU AU2012376221A patent/AU2012376221A1/en not_active Abandoned
- 2012-10-31 WO PCT/US2012/062850 patent/WO2013151584A1/en not_active Ceased
- 2012-10-31 JP JP2014540047A patent/JP6118808B2/ja not_active Expired - Fee Related
- 2012-10-31 CA CA2887928A patent/CA2887928A1/en not_active Abandoned
-
2014
- 2014-04-30 US US14/266,729 patent/US10555936B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013151584A1 (en) | 2013-10-10 |
| EP2804604A1 (en) | 2014-11-26 |
| US10555936B2 (en) | 2020-02-11 |
| CN104136026B (zh) | 2018-03-02 |
| US20140323513A1 (en) | 2014-10-30 |
| EP3815685A2 (en) | 2021-05-05 |
| CA2887928A1 (en) | 2013-10-10 |
| JP6118808B2 (ja) | 2017-04-19 |
| EP3815685A3 (en) | 2021-10-13 |
| KR102110794B1 (ko) | 2020-05-15 |
| KR20140128943A (ko) | 2014-11-06 |
| AU2012376221A1 (en) | 2014-06-19 |
| JP2014534227A (ja) | 2014-12-18 |
| CN104136026A (zh) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123010T1 (el) | Διεγερση γονιδιου τrail με μικρο μοριο απο κανονικα και ογκου κυτταρα ως αντικαρκινικη θεραπεια | |
| PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
| NZ754827A (en) | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | |
| MX2015002371A (es) | Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos. | |
| NZ706296A (en) | Glucosylceramide synthase inhibitors | |
| EP4559918A3 (en) | Glucosylceramide synthase inhibitors | |
| EP4406544A3 (en) | Cellular targeted active ingredient delivery system | |
| GB201203442D0 (en) | Immunotherapeutic molecules and uses | |
| CA3019531A1 (en) | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer | |
| TW201611843A (en) | Methods of treatment with arginine deiminase | |
| WO2012170776A3 (en) | Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy | |
| HK1204578A1 (en) | Medicament for the treatment of acute myeloid leukemia (aml) | |
| MX2013012785A (es) | Tratamiento del mieloma multiple. | |
| MY178390A (en) | Inhibitors of iap | |
| WO2013112699A3 (en) | Proteasome activity enhancing compounds | |
| HK1204547A1 (en) | Compound comprising a mao targeting/ seeker moiety for treating human gliomas | |
| MX2013015347A (es) | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). | |
| MX2013007055A (es) | Derivados de sanglifehrina y metodos para su produccion. | |
| HK1213500A1 (zh) | 用於胰腺导管腺癌的个体化治疗的新方法 | |
| PH12014502109A1 (en) | Methods of treating cancer using aurora kinase inhibitors | |
| WO2013142253A3 (en) | TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-c]PYRIDINES | |
| WO2012158776A3 (en) | Combination therapy for treatment of cancer | |
| UA35392U (ru) | Способ комплексной терапии злокачественных опухолей и метастазов |